nach oben

Erschienen in:

22.07.2019 | Clinical trial

Risk of malignancy in papillary neoplasms of the breast

verfasst von: Claire Liu, Ravi Sidhu, Avi Ostry, Rebecca Warburton, Jin-Si Pao, Carol Dingee, Urve Kuusk, Elaine McKevitt

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In recent years, routine excision of papillary neoplasms (PN) of the breast has been questioned and controversy exists over when excision is necessary. The aim of this study was to evaluate the upstage rate to malignancy of core needle biopsy (CNB) diagnosed PNs from multiple diagnostic centers in our area and to identify factors predictive of malignancy.

Methods

Patients presenting to our surgical center between 2013 and 2017 for excision of CNB PN were evaluated. The primary endpoint was upstage to malignancy. The association of age, diagnostic center where CNB performed, type of CNB, palpability, discharge, clinical exam size, imaging size, family history of breast cancer, and presence of atypia, as risk factors for upstaging to cancer were also evaluated.

Results

Of the 317 PN cases, 83 upstaged to malignancy following surgical excision. 77% of patients with CNB of Atypical PN upstaged, 39% of PN with concurrent atypical ductal hyperplasia, and 0% of PN with concurrent atypical lobular hyperplasia/flat epithelial atypia. Of the 206 non-atypical PNs on CNB, 3.4% upstaged to malignancy, but further review demonstrated a 1% upstage rate when atypia excluded. Factors found to be associated with malignancy included: older patient age, larger size, and presence of atypia.

Conclusion

We recommend excision of PN with atypia, concurrent cancerous lesion, or radiologic–pathologic non-concordance, and serial imaging follow up may be considered for image detected PN, less than 1 cm, with no atypia.

Rakha EA, Ellis IO (2018) Diagnostic challenges in papillary lesions of the breast. Pathology 50:100–110. https://doi.org/10.1016/j.pathol.2017.10.005 CrossRefPubMed

Menes TS, Rosenberg R, Balch S, Jaffer S, Kerlikowske K, Miglioretti DL (2014) Upgrade of high-risk breast lesions detected on mammography in the breast cancer surveillance consortium. Am J Surg 207:24–31. https://doi.org/10.1016/j.amjsurg.2013.05.014 CrossRefPubMed

Shiino S, Tsuda H, Yoshida M et al (2015) Intraductal papillomas on core biopsy can be upgraded to malignancy on subsequent excisional biopsy regardless of the presence of atypical features. Pathol Int 65:293–300. https://doi.org/10.1111/pin.12285 CrossRefPubMed

Khan S, Diaz A, Archer KJ et al (2018) Papillary lesions of the breast: to excise or observe? Breast J 24:350–355. https://doi.org/10.1111/tbj.12907 CrossRefPubMed

Hong YR, Song BJ, Jung SS et al (2016) Predictive factors for upgrading patients with benign breast papillary lesions using a core needle biopsy. J Breast Cancer 19:410–416. https://doi.org/10.4048/jbc.2016.19.4.410 CrossRefPubMedPubMedCentral

Han SH, Chung YR, Yun BL et al (2018) Benign Intraductal Papilloma without atypia on core needle biopsy has a low rate of upgrading to malignancy after excision. J Breast Cancer 21:80–86. https://doi.org/10.4048/jbc.2018.21.1.80 CrossRefPubMedPubMedCentral

Pareja F, Corben A, Brennan S et al (2016) Breast intraductal papilloma without atypia in radiologic-pathologic concordant core needle biopsies: rate of upgrade to carcinoma at excision. Cancer 122:2819–2827. https://doi.org/10.1002/cncr.30118 CrossRefPubMedPubMedCentral

Padilla-Thornton A, Farrell J, Gordon P et al (2018) Current evaluation of breast health concerns and diagnosis of breast cancer. BCMJ 60:27–32

Wen X, Cheng W (2013) Nonmalignant breast papillary lesions at core-needle biopsy: a meta analysis of underestimation and influencing factors. Ann Surg Oncol 20:94–101. https://doi.org/10.1245/s10434-012-2590-1 CrossRefPubMed

10.

Boin DP, Baez JJ, Guajardo MP et al (2014) Breast papillary lesions: an analysis of 70 cases. Ecancermedicalscience 8:461. https://doi.org/10.3332/ecancer.2014.461 CrossRefPubMedPubMedCentral

11.

Rizzo M, Lund MJ, Opera G, Schniederjan M, Wood WC, Mosunjac M (2008) Surgical follow-up and clinical presentation of 142, breast papillary lesions diagnosed by ultrasound-guided core-needle biopsy. Ann Surg Oncol 15:1040–1047. https://doi.org/10.1245/s10434-007-9780-2 CrossRefPubMed

12.

Ashkenazi I, Ferrer K, Sekosan M et al (2007) Papillary leisons of thebreast discovered on percutaneous large core vacuum-assisted biopsies: reliability of clinical and pathological parameters in identifying benign lesions. Am J Surg 194:183–188. https://doi.org/10.1016/j.amjsurg.2006.11.028 CrossRefPubMed

13.

Cyr AE, Novack D, Trinkaus K et al (2011) Are we overtreating papillomas diagnosed on core needle biopsy? Ann Surg Oncol 18:946–951. https://doi.org/10.1245/s10434-010-1403-7 CrossRefPubMed

14.

Sidhu R, MacKay E, Warburton R, Pao J, Kuusk U, Dingee C, McKevitt E (2018) Upstage to breast cancer after excision of atypical ductal hyperplasia on core needle of the breast-a regional experience. Ann Surg Oncol 25(2_suppl):341–342

15.

The American Society of Breast Surgeons (2016) Consensus guidelines on concordance assessment of image-guided breast biopsies and management of borderline or high-risk lesions. The American Society of Breast Surgeons. https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf. Accessed Mar 2019

16.

Becker AK, Gordon PB, Harrison DA, Hassell PR, Hayes MM, Niekerk D, Wilson CM (2013) Flat ductal intraepithelial neoplasia IA diagnosed at stereotactic core needle biopsy: is excisional biopsy indicated? AJR Am J Roentgenol 200:682–688. https://doi.org/10.2214/AJR.11.8090 CrossRefPubMed

17.

Agoumi M, Giambattista J, Hayes MM (2016) Practical considerations in breast papillary lesions: a review of the literature. Arch Pathol Lab Med 140:770–790. https://doi.org/10.5858/arpa.2015-0525-RA CrossRefPubMed

18.

Tse GM, Tan PH, Lui PC et al (2007) The role of immunohistochemistry for smooth-muscle actin, p63, CD10, and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 60:315–320. https://doi.org/10.1136/jcp.2006.036830 CrossRefPubMed

19.

Zhang H, Xiong Y, Zhang S, Zhang Y, Wang YH, Li T (2011) Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast [in Chinese]. Zhonghua Bing Li Xue Za Zhi 40:726–731. https://doi.org/10.3760/cma.j.issn.0529-5807.2011.11.002 CrossRefPubMed

20.

Omi Y, Yamamoto T, Okamoto T, Obara T, Kobayashi M (2011) A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis. Histol Histopathol 26:79–86. https://doi.org/10.14670/HH-26.79 CrossRefPubMed

21.

Tse GM, Tan PH, Moriya T (2009) The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 62:407–413. https://doi.org/10.1136/jcp.2008.06301 CrossRefPubMed

22.

Tan PH, Aw MY, Yip G et al (2005) Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Am J Surg Pathol 29:625–632. https://doi.org/10.1097/01.pas.0000157941.88161.39 CrossRefPubMed

23.

Grin A, O’Malley FP, Mulligan AM (2009) Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy. Am J Surg Pathol 33:1615–1623. https://doi.org/10.1097/PAS.0b013e3181aec446 CrossRefPubMed

24.

Schnitt S, Collins L (2008) Papillary lesions. In: Epstein JI (ed) Biopsy interpretation of the breast. Wolters Kluwer, Philadelphia, pp 205–235

25.

Tavassoli F, Devilee P (1999) Papillary lesions. In: Tavassoli F (ed) Pathology of the Breast, 2nd edn. McGraw-Hill, New York, pp 325–372

26.

Tan PH, Schnitt SJ, van der Vijver MJ, Ellis IO, Lakhani SR (2015) Papillary and neuroendocrine breast lesions: the WHO stance. Histopathology 66:761–770. https://doi.org/10.1111/his.12463 CrossRefPubMed

27.

Page DL, Salhany KE, Jensen RA, Dupont WD (1996) Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Cancer 78:258–266. https://doi.org/10.1002/(SICI)1097-0142(19960715)78:2%3c258:AID-CNCR27%3e3.0.CO;2-V CrossRefPubMed

28.

Lewis JT, Hartmann LC, Vierkant RA et al (2006) An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol 30:665–672CrossRef

29.

Putti TC, Pinder SE, Elston CW, Lee AH, Ellis IO (2005) Breast pathology practice: most common problems in a consultation service. Histopathology 47:445–457. https://doi.org/10.1111/j.1365-2559.2005.02246.x CrossRefPubMed

30.

McKevitt E, Warburton R, Pao J, Kuusk U, Dingee C, Brown C (2017) Breast cancer surgery wait times exceeding targets with current OR allocation methodology. Meeting of the British Columbia Surgical Society, Parksville, BC, May 2017

Titel: Risk of malignancy in papillary neoplasms of the breast
verfasst von: Claire Liu
Ravi Sidhu
Avi Ostry
Rebecca Warburton
Jin-Si Pao
Carol Dingee
Urve Kuusk
Elaine McKevitt
Publikationsdatum: 22.07.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05367-w

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Risk of malignancy in papillary neoplasms of the breast